Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also recently commented on AIMT. Roth Capital started coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They set a “buy” rating and a $60.00 target price for the company. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Wedbush reaffirmed an “ourperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Piper Jaffray Companies lifted their price target on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $53.80.

Aimmune Therapeutics (NASDAQ:AIMT) opened at $34.16 on Friday. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. research analysts anticipate that Aimmune Therapeutics will post -2.54 EPS for the current year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 47,425 shares of Aimmune Therapeutics stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the sale, the insider now owns 34,300 shares of the company’s stock, valued at $1,181,292. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 274,986 shares of company stock valued at $7,533,100. Corporate insiders own 24.56% of the company’s stock.

A number of hedge funds have recently modified their holdings of AIMT. Teachers Advisors LLC lifted its stake in Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 1,120 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Aimmune Therapeutics by 5.3% in the 1st quarter. Geode Capital Management LLC now owns 207,210 shares of the biotechnology company’s stock valued at $4,502,000 after acquiring an additional 10,461 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Aimmune Therapeutics by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock valued at $1,892,000 after acquiring an additional 4,788 shares during the last quarter. State Street Corp lifted its stake in shares of Aimmune Therapeutics by 49.1% in the 1st quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after acquiring an additional 282,744 shares during the last quarter. Finally, Credit Suisse AG lifted its stake in shares of Aimmune Therapeutics by 14.1% in the 1st quarter. Credit Suisse AG now owns 42,445 shares of the biotechnology company’s stock valued at $924,000 after acquiring an additional 5,248 shares during the last quarter. 73.34% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Aimmune Therapeutics (AIMT) Downgraded by BidaskClub to Hold” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/09/aimmune-therapeutics-aimt-downgraded-by-bidaskclub-to-hold.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.